Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study
Kong Boo Phua(KK Women's and Children's Hospital), Filip Lim(SingHealth Polyclinics), YL Lau, E. Anthony S. Nelson(Chinese University of Hong Kong), Li‐Min Huang(National Taiwan University Hospital), Seng Hock Quak(National University of Singapore), B.W. Lee(Mount Elizabeth Hospital), Yee Leong Teoh(SingHealth Polyclinics), Haïwen Tang(GlaxoSmithKline (United Kingdom)), Irving Charles Boudville(GlaxoSmithKline (United Kingdom)), Lidia Oostvogels(GlaxoSmithKline (United Kingdom)), P.V. Suryakiran(GlaxoSmithKline (United Kingdom)), Igor Smolenov(GlaxoSmithKline (United Kingdom)), Hongying Han(GlaxoSmithKline (United Kingdom)), H.L. Bock(GlaxoSmithKline (United Kingdom))
Cited by 142
Abstract
Related Papers
Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine
Timo Vesikari, David O. Matson, Penelope H. Dennehy et al.|New England Journal of Medicine|2006|1.9k
Rotavirus and Severe Childhood Diarrhea
Umesh D. Parashar, Christopher J. Gibson, Joseph Bresee et al.|Emerging infectious diseases|2006|1.5k